General American Investors Co. Inc. Boosts Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

General American Investors Co. Inc. increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILDGet Rating) by 0.2% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 101,100 shares of the biopharmaceutical company’s stock after buying an additional 200 shares during the period. General American Investors Co. Inc.’s holdings in Gilead Sciences were worth $7,341,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the company. OLD Second National Bank of Aurora increased its stake in shares of Gilead Sciences by 46.3% in the third quarter. OLD Second National Bank of Aurora now owns 439 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 139 shares in the last quarter. Impax Asset Management Group plc increased its stake in shares of Gilead Sciences by 0.4% in the third quarter. Impax Asset Management Group plc now owns 40,201 shares of the biopharmaceutical company’s stock worth $2,808,000 after purchasing an additional 149 shares in the last quarter. Key Financial Inc increased its stake in shares of Gilead Sciences by 3.7% in the fourth quarter. Key Financial Inc now owns 4,228 shares of the biopharmaceutical company’s stock worth $307,000 after purchasing an additional 151 shares in the last quarter. Trust Investment Advisors increased its stake in shares of Gilead Sciences by 1.3% in the fourth quarter. Trust Investment Advisors now owns 12,243 shares of the biopharmaceutical company’s stock worth $889,000 after purchasing an additional 153 shares in the last quarter. Finally, Equitable Holdings Inc. increased its stake in shares of Gilead Sciences by 0.4% in the third quarter. Equitable Holdings Inc. now owns 41,253 shares of the biopharmaceutical company’s stock worth $2,882,000 after purchasing an additional 156 shares in the last quarter. Hedge funds and other institutional investors own 80.16% of the company’s stock.

Shares of GILD stock traded up $0.94 during trading hours on Tuesday, hitting $63.18. 5,607,361 shares of the company’s stock were exchanged, compared to its average volume of 10,281,857. The company has a market capitalization of $79.25 billion, a PE ratio of 17.65, a PEG ratio of 0.44 and a beta of 0.38. Gilead Sciences, Inc. has a 12-month low of $57.19 and a 12-month high of $74.12. The business’s 50 day simple moving average is $60.75 and its 200-day simple moving average is $65.21. The company has a current ratio of 1.48, a quick ratio of 1.30 and a debt-to-equity ratio of 1.31.

Gilead Sciences (NASDAQ:GILDGet Rating) last posted its quarterly earnings results on Thursday, April 28th. The biopharmaceutical company reported $2.12 EPS for the quarter, topping the consensus estimate of $1.77 by $0.35. The firm had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.28 billion. Gilead Sciences had a net margin of 16.43% and a return on equity of 44.98%. The business’s revenue was up 2.6% compared to the same quarter last year. During the same period last year, the firm posted $2.08 earnings per share. Equities analysts anticipate that Gilead Sciences, Inc. will post 6.62 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, June 29th. Investors of record on Wednesday, June 15th will be paid a $0.73 dividend. This represents a $2.92 annualized dividend and a dividend yield of 4.62%. The ex-dividend date of this dividend is Tuesday, June 14th. Gilead Sciences’s payout ratio is 81.56%.

Several equities analysts have recently weighed in on GILD shares. Morgan Stanley reduced their target price on shares of Gilead Sciences from $69.00 to $63.00 and set an “equal weight” rating for the company in a research note on Tuesday, April 12th. BMO Capital Markets assumed coverage on shares of Gilead Sciences in a research report on Tuesday, March 8th. They issued a “hold” rating and a $65.00 price objective for the company. Argus upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $75.00 price objective for the company in a research report on Friday, January 28th. Barclays cut their price objective on shares of Gilead Sciences from $63.00 to $56.00 and set an “underweight” rating for the company in a research report on Thursday, March 10th. Finally, Truist Financial cut their price objective on shares of Gilead Sciences from $77.00 to $75.00 and set a “hold” rating for the company in a research report on Wednesday, February 2nd. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $72.67.

In related news, EVP Brett A. Pletcher sold 3,634 shares of Gilead Sciences stock in a transaction on Friday, March 11th. The shares were sold at an average price of $58.24, for a total value of $211,644.16. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 0.16% of the stock is owned by insiders.

About Gilead Sciences (Get Rating)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

Read More

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.